| Market Capitalization (Millions $) |
264 |
| Shares
Outstanding (Millions) |
23 |
| Employees |
161 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-248 |
| Cash Flow (TTM) (Millions $) |
-8 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Lyell Immunopharma Inc is a biotechnology company focused on the development of next-generation cell therapies for cancer treatment. The company is headquartered in South San Francisco, California, and is led by CEO and co-founder, Rick Klausner. The company was founded in 2018, and has raised over $493 million in funding to date.
Lyell Immunopharma's mission is to transform cancer treatment by developing new cell therapies that enhance the body's natural immune system to fight cancer. The company is focused on developing personalized cell therapies that target specific types of cancer, improving the effectiveness of current treatments and reducing the side effects associated with traditional treatments.
Lyell Immunopharma is developing a platform that combines the latest advances in synthetic biology with sophisticated gene editing technologies to create powerful immune cells that can specifically target cancer cells. The company's proprietary technology is based on a novel approach called Synthetic Control of Cellular Circuits (SynC3), which enables the design of precise and customizable cell therapies that can respond to changing conditions within the body.
Lyell Immunopharma's lead product candidate is LY-501, a personalized cell therapy that targets solid tumors. The company is currently conducting Phase 1 clinical trials to evaluate the safety and efficacy of LY-501 in patients with advanced solid tumors. The company also has several other programs in preclinical development, including CAR-T and TCR therapies for different types of cancer.
Lyell Immunopharma has received significant funding from several high-profile investors, including ARCH Venture Partners, Foresite Capital, and the Alaska Permanent Fund. The company also has partnerships with several leading academic institutions, including the University of California, San Francisco, and the Massachusetts Institute of Technology.
In summary, Lyell Immunopharma is a biotechnology company that is focused on developing next-generation cell therapies for cancer treatment. The company's mission is to transform cancer treatment by developing personalized cell therapies that enhance the body's natural immune system to fight cancer. With its proprietary SynC3 platform, the company is developing powerful and customizable cell therapies that can respond to changing conditions within the body. The company's lead product candidate, LY-501, is currently in clinical trials and the company has several other programs in preclinical development.
Company Address: 201 Haskins Way South San Francisco 94080 CA
Company Phone Number: 695-0677 Stock Exchange / Ticker: NASDAQ LYEL
|
28.34% 
150 %